利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.018 秒)

    Method of Treating a Proliferative Disease
    1.
    发明申请
    Method of Treating a Proliferative Disease 审中-公开
    治疗增生性疾病的方法

    公开(公告)号：US20140275136A1

    公开(公告)日：2014-09-18

    申请号：US14355903

    申请日：2012-11-09

    申请人： NOVARTIS AG

    发明人： Darrin Stuart ,  Meghna Das Thakur

    IPC分类号： A61K31/506

    CPC分类号： A61K31/506

    摘要： The present invention relates to a method of treating a patient with a serine/threonine kinase inhibitor wherein resistance to the treatment with a serine/threonine kinase inhibitor is suppressed by administering the serine/threonine kinase inhibitor on an intermittent dosing schedule.

    摘要翻译： 本发明涉及一种用丝氨酸/苏氨酸激酶抑制剂治疗患者的方法，其中通过以间歇给药方案施用丝氨酸/苏氨酸激酶抑制剂来抑制对丝氨酸/苏氨酸激酶抑制剂的治疗的抗性。

    Pharmaceutical Combinations of a CDK4/6 Inhibitor and a B-RAF Inhibitor
    3.
    发明申请
    Pharmaceutical Combinations of a CDK4/6 Inhibitor and a B-RAF Inhibitor 有权
    CDK4 / 6抑制剂和B-RAF抑制剂的药物组合

    公开(公告)号：US20150164897A1

    公开(公告)日：2015-06-18

    申请号：US14414998

    申请日：2013-07-25

    申请人： NOVARTIS AG

    发明人： Giordano Caponigro ,  Darrin Stuart ,  Sunkyu Kim ,  Alice Loo ,  Scott Delach

    IPC分类号： A61K31/519 ,  A61K31/4184 ,  A61K31/506

    CPC分类号： A61K31/519 ,  A61K31/4184 ,  A61K31/506 ,  A61K2300/00

    摘要： A pharmaceutical combination comprising (a) CDK4/6 inhibitor (b) a B-Raf inhibitor, and optionally (c) a MEK 1/2 inhibitor; combined preparations and pharmaceutical compositions thereof; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

    摘要翻译： 一种药物组合，其包含（a）CDK4 / 6抑制剂（b）B-Raf抑制剂和任选的（c）MEK 1/2抑制剂; 联合制剂及其药物组合物; 这种组合在增殖性疾病治疗中的应用; 以及治疗患有增殖性疾病的受试者的方法，包括施用治疗有效量的这种组合。

    Therapeutic uses of a C-RAF inhibitor
    4.
    发明授权
    Therapeutic uses of a C-RAF inhibitor 有权

    公开(公告)号：US10973829B2

    公开(公告)日：2021-04-13

    申请号：US16332120

    申请日：2017-09-18

    申请人： Novartis AG

    发明人： Giordano Caponigro ,  Vesselina Cooke ,  Matthew John Meyer ,  Darrin Stuart

    IPC分类号： A61K31/5377 ,  A61P35/00 ,  A61K31/4965

    摘要： The present invention relates to a combination treatment which comprises (a) at least one ERK inhibitor preferably Compound B as described herein, and (b) a c-RAF inhibitor or a pharmaceutically acceptable salt thereof, preferably Compound A, which may be combined into a single pharmaceutical composition or prepared for separate or sequential administration. It includes a c-RAF inhibitor and an ERK inhibitor prepared for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly an advanced solid tumor that harbors a Mitogen-activated protein kinase (MAPK) alteration, and includes methods of using these compounds in combination as well as a commercial package comprising such combination.

    Therapeutic combinations comprising a c-RAF inhibitor
    5.
    发明授权
    Therapeutic combinations comprising a c-RAF inhibitor 有权

    公开(公告)号：US12011449B2

    公开(公告)日：2024-06-18

    申请号：US17191205

    申请日：2021-03-03

    申请人： Novartis AG

    发明人： Giordano Caponigro ,  Vesselina Cooke ,  Matthew John Meyer ,  Darrin Stuart

    IPC分类号： A61K31/5377 ,  A61K31/4965 ,  A61P35/00

    CPC分类号： A61K31/5377 ,  A61K31/4965 ,  A61P35/00

    摘要： The present invention relates to a combination treatment which comprises (a) at least one ERK inhibitor preferably Compound B as described herein, and (b) a c-RAF inhibitor or a pharmaceutically acceptable salt thereof, preferably Compound A, which may be combined into a single pharmaceutical composition or prepared for separate or sequential administration. It includes a c-RAF inhibitor and an ERK inhibitor prepared for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly an advanced solid tumor that harbors a Mitogen-activated protein kinase (MAPK) alteration, and includes methods of using these compounds in combination as well as a commercial package comprising such combination.